UMT Co., Ltd. is a pioneering leader in new drug development, driving innovation in drug discovery and healthcare solutions. Our distinctive research and development expertise spans a wide range of therapeutic areas, including sarcopenia and rare diseases. Backed by extensive clinical development experience and a dedicated expert team, we focus on acquiring proprietary technologies, fostering collaborative partnerships, and advancing global commercialization to bring patient-focused, innovative therapies to market.

Furthermore, UMT actively strengthens partnerships with academia, research institutes, and medical networks to continuously expand evidence-based drug development. Through this integrated ecosystem, we are committed to advancing scientific innovation and establishing ourselves as a trusted leader in the global pharmaceutical industry.

CDA-01 is a botanical drug under development based on peony root extract for the treatment of sarcopenia and as an individually recognized material for improving muscle strength. It is a next-generation innovative solution aimed at promoting healthy aging and enhancing muscle health through scientific research.